Concepedia

Edmund Luo

EL

Statistics

Publications

4

Citations

1.2K

H-Index

4

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Edmund Luo is an author at Merck & Co., Inc., Rahway, NJ, USA (United States).

Publications per year

2007–2011

4

Publications

4

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Kjeld Hermansen, Mark Kipnes, Edmund Luo et al. · Diabetes Obesity and Metabolism · 2007 · 522 citations · Full text

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

Tina Vilsbøll, Julio Rosenstock, H Yki-Järvinen et al. · Diabetes Obesity and Metabolism · 2009 · 303 citations · Full text

Effects of MK-0941, a Novel Glucokinase Activator, on Glycemic Control in Insulin-Treated Patients With Type 2 Diabetes

Gary Meininger, Russell Scott, Maria Alba et al. · Diabetes Care · 2011 · 211 citations · Full text

Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study

Debora Williams‐Herman, Jeremy Johnson, R. Teng et al. · Current Medical Research and Opinion · 2009 · 127 citations

1–4 of 4